Inrebic

Inrebic is a brand name for the drug fedratinib. It is a prescription medication used to treat adults with intermediate-2 or high-risk primary or secondary myelofibrosis. Myelofibrosis is a bone marrow disorder that disrupts the normal production of blood cells. Inrebic is a Janus kinase (JAK) inhibitor. JAKs are enzymes that play a role in the signaling pathways that regulate blood cell production and inflammation. By inhibiting these enzymes, fedratinib helps to reduce the abnormal production of blood cells and inflammation associated with myelofibrosis. Inrebic is taken orally, typically once a day. It is important to note that Inrebic can cause serious side effects, including a rare but serious brain infection called West Nile virus neuroinvasive disease. Other potential side effects include anemia, thrombocytopenia (low platelet count), neutropenia (low white blood cell count), gastrointestinal issues, and fatigue. It is crucial for patients to discuss the risks and benefits of Inrebic with their healthcare provider and to undergo regular monitoring as recommended. The dosage and duration of treatment are determined by the prescribing physician based on individual patient response and medical history.